Johnson & Johnson posted quarterly revenue of $25.31 billion on July 15, beating Wall Street expectations and raising its full-year guidance. The healthcare giant has now set itself on course to exceed $100 billion in annual revenue for the first time in its 140-year history.

The company delivered adjusted earnings per share of $2.90, ahead of consensus estimates of $2.85. Net earnings were $5.53 billion, while adjusted net earnings climbed 5.7% to $7.08 billion, driven by strong performance in immunology and oncology drugs.

Immunology and Oncology Lead Growth

Tremfya, the company’s immunology treatment, showed robust growth across its portfolio. The cancer blockbuster Darzalex continued to perform strongly, offsetting erosion in older products. These two franchises provided the firepower that pushed J&J ahead of forecasts.

The company’s acquisition of Abiomed in 2022 had been expected to boost revenues. Instead, sales for the heart pump business declined, suggesting market headwinds in that segment even as other units accelerated.

Full-Year Path Clears

With Q2 results in hand and new guidance raised, J&J is on track to hit its landmark $100 billion annual revenue target. The company cited strength across its pharmaceutical and medical devices businesses as the foundation for confidence in the outlook.

Management emphasized that immunology and oncology remain the key growth engines going forward. The company is investing heavily in next-generation therapies in these areas.

Investors now have clarity on J&J’s momentum heading into the second half. The stock market will watch closely whether management can sustain this pace through year-end.